You are here

TGA Internet site archive

The content on this page and other TGA archive pages is provided to assist research and may contain references to activities or policies that have no current application. See the full archive disclaimer.

CMEC Meeting 45, 23 April 2004

Complementary Medicines Evaluation Committee

23 April 2004

Extracted ratified minutes

How to access a pdf document

CMEC Meeting 45 extracted ratified minutes (pdf,94kb)

Public recommendation summary

This summary has been posted immediately after the CMEC meeting to give quick advice of the recommendations made by CMEC to the TGA. This summary does not represent the decisions of TGA. Reasons underlying these recommendations will be available after Members ratify the Minutes at the next CMEC meeting.

Item 2 Minutes of CMEC's 44th meeting

Recommendation 45.1

CMEC confirms that the draft Minutes of its previous meeting (CMEC 44, 13 February 2004), as amended, are a true and accurate record of that previous meeting.

Item 5 Actions arising from previous meetings

Item 5.1 Action arising from previous meetings - Application for the evaluation of a new substance: iron phosphate (British Pharmaceutical Codex 1973)

Recommendation 45.2

CMEC recommends to TGA that iron phosphate (British Pharmaceutical Codex 1973) is suitable for use as an ingredient in Listed medicines.

Recommendation 45.3

CMEC further recommends to TGA that the need for child-resistant packaging for Listed iron products be reviewed.

Item 5.2 Action arising from previous meetings - Safety review: rutin

Recommendation 45.4

CMEC notes the review of safety of rutin conducted by the TGA and recommends to TGA that it is suitable for use as an ingredient in Listed medicines.

Item 6.1 Application for the evaluation of a new substance: Leptospermum petersonii oil (up to 5 %)

Recommendation 45.5

CMEC recommends to TGA that Leptospermum petersonii oil is suitable for use as an excipient ingredient up to 5% concentration in Listed topical medicines only.

Item 7.1 Safety review: glucosamine

Recommendation 45.6

CMEC notes a review of Australian adverse drug reaction data for glucosamine conducted by the TGA and recommends to TGA that glucosamine continues to be suitable for use as an ingredient in Listed medicines.

Top of page